Our Sites » TechNews TechDatabase Canadian Private Equity Register     Login

Home » Product, Business Development » Welichem Biotech and Stiefel in $50 million WBI-1001 deal

Welichem Biotech and Stiefel in $50 million WBI-1001 deal

Welichem Biotech Inc. (TSX-V: WBI) has entered into an exclusive agreement with Stiefel, a GSK company, pursuant to which Stiefel has agreed to acquire the exclusive development and commercialization rights to Welichem... 

To Read This Article, please Login





See Also:

Copyright © 2013 TechFinance.ca. All rights reserved. | Healthy Living | wp-tips.
More in Product, Business Development (6 of 82 articles)


...